Mouse Monoclonal GRIA2 Antibody

The GRIA2 antibody targets the glutamate ionotropic receptor AMPA type subunit 2 (GRIA2 or GluA2), a critical component of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. These receptors mediate fast excitatory synaptic transmission in the central nervous system and play essential roles in synaptic plasticity, learning, and memory. The GRIA2 subunit determines key functional properties of AMPA receptors, including calcium permeability and receptor trafficking. Unlike other AMPA receptor subunits, most GluA2 undergoes RNA editing at the Q/R site, which renders the receptor impermeable to calcium and regulates its synaptic stability. Dysregulation of GRIA2 expression or function has been implicated in neurological disorders such as epilepsy, Alzheimer’s disease, and neuropsychiatric conditions. Antibodies against GRIA2 are widely used in neuroscience research to study receptor localization, expression levels, and post-translational modifications in both healthy and diseased tissues. They are employed in techniques like immunohistochemistry, Western blotting, and immunofluorescence to explore synaptic changes in models of neurodegeneration, ischemia, or psychiatric disorders. Commercially available GRIA2 antibodies are typically validated for specificity against human, mouse, or rat samples, though cross-reactivity with other species may vary. Researchers often use these antibodies to investigate AMPA receptor composition alterations in conditions like autism spectrum disorders or addiction, where glutamatergic signaling is disrupted. Proper controls, such as knockout tissue or peptide competition, are critical to confirm antibody specificity.